Tower Research Capital (TRC)’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,629
| Closed | -$835 | – | 5988 |
|
|
2024
Q4 | $835 | Buy |
3,629
+3,383
| +1,375% | +$4.06K | ﹤0.01% | 5156 |
|
|
2024
Q3 | $529 | Sell |
246
-2,606
| -91% | -$9.36K | ﹤0.01% | 5318 |
|
|
2024
Q2 | $14.7K | Buy |
2,852
+2,757
| +2,902% | +$14.5K | ﹤0.01% | 3938 |
|
|
2024
Q1 | $508 | Buy |
+95
| New | +$657 | ﹤0.01% | 5460 |
|
|
2023
Q2 | – | Sell |
-6,584
| Closed | -$18K | – | 6420 |
|
|
2023
Q1 | $18K | Sell |
6,584
-5,478
| -45% | -$21.2K | ﹤0.01% | 3593 |
|
|
2022
Q4 | $43K | Buy |
12,062
+9,410
| +355% | +$40.8K | ﹤0.01% | 2476 |
|
|
2022
Q3 | $17K | Buy |
2,652
+1,718
| +184% | +$14K | ﹤0.01% | 4089 |
|
|
2022
Q2 | $9K | Sell |
934
-2,343
| -71% | -$21.9K | ﹤0.01% | 4603 |
|
|
2022
Q1 | $39K | Buy |
3,277
+700
| +27% | +$12.5K | ﹤0.01% | 2927 |
|
|
2021
Q4 | $84K | Buy |
2,577
+1,360
| +112% | +$55.1K | ﹤0.01% | 2353 |
|
|
2021
Q3 | $54K | Sell |
1,217
-1,288
| -51% | -$62.9K | ﹤0.01% | 2906 |
|
|
2021
Q2 | $136K | Sell |
2,505
-945
| -27% | -$55.9K | ﹤0.01% | 2180 |
|
|
2021
Q1 | $258K | Buy |
3,450
+2,087
| +153% | +$217K | ﹤0.01% | 1786 |
|
|
2020
Q4 | $148K | Sell |
1,363
-683
| -33% | -$62.3K | ﹤0.01% | 1995 |
|
|
2020
Q3 | $181K | Buy |
2,046
+1,213
| +146% | +$138K | ﹤0.01% | 2670 |
|
|
2020
Q2 | $89K | Buy |
+833
| New | +$74.8K | ﹤0.01% | 2566 |
|
|
2019
Q4 | – | Sell |
-269
| Closed | -$28K | – | 4519 |
|
|
2019
Q3 | $28K | Buy |
269
+241
| +861% | +$22.8K | ﹤0.01% | 2243 |
|
|
2019
Q2 | $3K | Buy |
+28
| New | +$1.95K | ﹤0.01% | 3180 |
|
|
2019
Q1 | – | Sell |
-913
| Closed | -$50K | – | 4375 |
|
|
2018
Q4 | $50K | Buy |
913
+811
| +795% | +$61.6K | ﹤0.01% | 1293 |
|
|
2018
Q3 | $12K | Sell |
102
-82
| -45% | -$9.51K | ﹤0.01% | 2668 |
|
|
2018
Q2 | $19K | Buy |
+184
| New | +$22.8K | ﹤0.01% | 2478 |
|
|
2018
Q1 | – | Sell |
-2,187
| Closed | -$213K | – | 3947 |
|
|
2017
Q4 | $213K | Buy |
2,187
+1,381
| +171% | +$185K | 0.03% | 543 |
|
|
2017
Q3 | $118K | Buy |
+806
| New | +$152K | 0.01% | 1196 |
|
|
2017
Q2 | – | Sell |
-5
| Closed | -$1K | – | 3576 |
|
|
2017
Q1 | $1K | Buy |
5
+2
| +67% | +$244 | ﹤0.01% | 2871 |
|
|
2016
Q4 | $0 | Sell |
3
-151
| -98% | -$21.2K | ﹤0.01% | 4497 |
|
|
2016
Q3 | $21K | Buy |
+154
| New | +$19.5K | ﹤0.01% | 1592 |
|
Other funds holding SYRS
BBA
1CM
XT
Tower Research Capital (TRC)'s SYRS Position: Q1 2025 in Review
Tower Research Capital (TRC) sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 3,629 shares — an estimated $835 sold.
Tower Research Capital (TRC) first reported a position in SYRS in Q3 2016 and held it in 26 quarters. The position peaked at $258K in Q1 2021. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.
- Tower Research Capital (TRC) reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,629 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $835.
- Tower Research Capital (TRC) first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 26 quarters.
- Tower Research Capital (TRC)'s Syros Pharmaceuticals, Inc. Common Stock position peaked at $258K in Q1 2021.
- 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.